Cubist Systematic Strategies, LLC Biogen Inc. Transaction History

Cubist Systematic Strategies, LLC

$14.3 Billion
Q2 2024

A detailed history of Cubist Systematic Strategies, LLC transactions in Biogen Inc. stock. As of the latest transaction made, Cubist Systematic Strategies, LLC holds 3,200 shares of BIIB stock, worth $556,128. This represents 0.01% of its overall portfolio holdings.

Number of Shares

3,200

Previous 3,200 -0.0%

Holding current value

$556,128

Previous $741,000 -0.0%

% of portfolio

0.01%

Previous 0.01%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$212.02 - $267.71 $2.01 Million - $2.54 Million	9,502 Added 92.33%	19,793 $4.27 Million
Q4 2023 Feb 14, 2024	BUY	$222.59 - $267.94 $1.77 Million - $2.13 Million	7,947 Added 339.04%	10,291 $2.66 Million
Q3 2023 Nov 14, 2023	BUY	$253.3 - $285.89 $414,905 - $468,287	1,638 Added 232.01%	2,344 $602,000
Q2 2023 Aug 14, 2023	SELL	$275.25 - $318.06 $295,343 - $341,278	-1,073 Reduced 60.31%	706 $201,000
Q1 2023 May 15, 2023	SELL	$256.56 - $292.34 $15.5 Million - $17.7 Million	-60,495 Reduced 97.14%	1,779 $494,000
Q4 2022 Feb 14, 2023	SELL	$252.44 - $306.72 $12 Million - $14.6 Million	-47,692 Reduced 43.37%	62,274 $17.2 Million
Q3 2022 Nov 14, 2022	BUY	$194.69 - $268.46 $15.6 Million - $21.5 Million	80,194 Added 269.36%	109,966 $29.4 Million
Q2 2022 Aug 15, 2022	SELL	$187.54 - $223.02 $16.5 Million - $19.6 Million	-88,061 Reduced 74.73%	29,772 $6.07 Million
Q1 2022 May 16, 2022	BUY	$193.77 - $244.14 $16.9 Million - $21.3 Million	87,165 Added 284.22%	117,833 $24.8 Million
Q4 2021 Feb 14, 2022	BUY	$223.92 - $287.77 $3.96 Million - $5.09 Million	17,700 Added 136.49%	30,668 $7.36 Million
Q3 2021 Nov 15, 2021	SELL	$282.99 - $369.05 $6.72 Million - $8.76 Million	-23,740 Reduced 64.67%	12,968 $3.67 Million
Q2 2021 Aug 16, 2021	BUY	$259.0 - $414.71 $8.33 Million - $13.3 Million	32,173 Added 709.44%	36,708 $12.7 Million
Q1 2021 May 17, 2021	SELL	$242.95 - $284.63 $1.13 Million - $1.32 Million	-4,640 Reduced 50.57%	4,535 $1.27 Million
Q4 2020 Feb 16, 2021	SELL	$236.26 - $355.63 $206,491 - $310,820	-874 Reduced 8.7%	9,175 $2.25 Million
Q3 2020 Nov 16, 2020	SELL	$264.77 - $305.71 $1.28 Million - $1.48 Million	-4,839 Reduced 32.5%	10,049 $2.85 Million
Q2 2020 Aug 14, 2020	SELL	$258.66 - $342.55 $2.33 Million - $3.08 Million	-8,998 Reduced 37.67%	14,888 $3.98 Million
Q1 2020 May 15, 2020	BUY	$268.85 - $341.04 $1.72 Million - $2.18 Million	6,381 Added 36.45%	23,886 $7.56 Million
Q4 2019 Feb 14, 2020	SELL	$220.06 - $304.07 $11.9 Million - $16.5 Million	-54,151 Reduced 75.57%	17,505 $5.19 Million
Q3 2019 Nov 14, 2019	BUY	$217.44 - $243.88 $2.66 Million - $2.98 Million	12,230 Added 20.58%	71,656 $16.7 Million
Q2 2019 Aug 14, 2019	BUY	$219.29 - $241.72 $12 Million - $13.2 Million	54,549 Added 1118.49%	59,426 $13.9 Million
Q1 2019 May 15, 2019	SELL	$216.71 - $338.96 $2.69 Million - $4.21 Million	-12,406 Reduced 71.78%	4,877 $1.15 Million
Q4 2018 Feb 14, 2019	SELL	$278.5 - $352.75 $6.49 Million - $8.22 Million	-23,301 Reduced 57.41%	17,283 $5.2 Million
Q3 2018 Nov 14, 2018	BUY	$293.51 - $383.83 $10.6 Million - $13.8 Million	35,981 Added 781.69%	40,584 $14.3 Million
Q2 2018 Aug 14, 2018	BUY	$257.52 - $306.91 $207,303 - $247,062	805 Added 21.2%	4,603 $1.34 Million
Q1 2018 May 15, 2018	SELL	$260.13 - $367.91 $3.19 Million - $4.5 Million	-12,244 Reduced 76.32%	3,798 $1.04 Million
Q4 2017 Feb 14, 2018	BUY	$307.64 - $344.58 $1.66 Million - $1.86 Million	5,396 Added 50.69%	16,042 $5.11 Million
Q3 2017 Nov 14, 2017	BUY	$281.15 - $329.69 $2.99 Million - $3.51 Million	10,646	10,646 $3.33 Million

Others Institutions Holding BIIB

# of Institutions

1,018

Shares Held

128M

Call Options Held

1.22M

Put Options Held

1.4M

View Full List

About BIOGEN INC.

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $25B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

More about BIIB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.

Account

Cubist Systematic Strategies, LLC Biogen Inc. Transaction History